不在灌木丛中
发表于 2025-3-27 00:28:40
http://reply.papertrans.cn/43/4202/420174/420174_31.png
巧思
发表于 2025-3-27 01:26:17
HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombroved IFN-sparing DAA therapies (Viekira Pak™ and Technivie™) with approval to treat genotypes 1 and 4, respectively. PIB, a next-generation NS5A inhibitor included in AbbVie’s next-generation therapy Mavyret™ (or Maviret™), prevents replication of HCV genotypes 1–6 and exhibits an improved resistan
Virtues
发表于 2025-3-27 08:46:16
The Evolution of Clinical Trials for Hepatitis Crology, has been solidified based on the combination of our understanding of the molecular biology of the virus and the rarity, dating back to the interferon era, of virologic relapse after attainment of sustained virologic response. Although, at least until recently, the number of therapeutic agent
Malaise
发表于 2025-3-27 12:05:03
http://reply.papertrans.cn/43/4202/420174/420174_34.png
ARY
发表于 2025-3-27 16:06:18
The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®)Ss). The Phase 3 studies enrolled and treated over 1,000 genotype 1–6 HCV-infected patients with 12 weeks of SOF/VEL. In patients with compensated cirrhosis, the overall SVR rate was 98%, and with SOF/VEL + RBV in patients with decompensated cirrhosis, the SVR rate was 94%. With minimal drug-drug in
phlegm
发表于 2025-3-27 19:46:48
http://reply.papertrans.cn/43/4202/420174/420174_36.png
繁荣地区
发表于 2025-3-27 23:39:33
http://reply.papertrans.cn/43/4202/420174/420174_37.png
thrombosis
发表于 2025-3-28 03:50:26
Development of ZEPATIER®to the approval of the elbasvir/grazoprevir combination therapy for the treatment of people with HCV genotype 1 or genotype 4 infection in the United States, Europe, Canada, and many other countries worldwide.
prostate-gland
发表于 2025-3-28 08:24:08
The Benefit of Direct-Acting Antiviral HCV Cure Therapiesr to SVR underwent a biopsy after SVR. However, the post-SVR liver biopsies of only 4 patients showed F1–F2, while 11 patients still showed F3–F4, indicating that TE improvements are overstated when compared to histologic staging and that patients with cirrhosis before DAA therapy need to be monitor
配偶
发表于 2025-3-28 13:37:27
NS5A as a Target for HCV Drug Discoveryfort by academic and pharmaceutical researchers, HCV infection is a curable disease. In fact, HCV is the first chronic infectious disease to be cured with combinations of direct antiviral agents. Among these antiviral agents, NS5A inhibitors are the most potent. The unprecedented low pM potency, pan